Related Experiment Video

Updated: Aug 17, 2026

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors
09:04

A Simple Bioassay for the Evaluation of Vascular Endothelial Growth Factors

Published on: March 15, 2016

[New molecular target of cancer therapy--angiogenesis regulator VEGF]

M Toi1, T Ueno, T Tominaga

  • 1Dept. of Surgery, Tokyo Metropolitan Komagome Hospital, Japan.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|January 9, 1998
PubMed

Insights

Vascular Endothelial Growth Factor (VEGF) is a key target for suppressing tumor growth. This review explores therapeutic strategies to control VEGF function in human solid tumors, highlighting its role in neovascularization.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biomedical Research

Background:

  • Angiogenesis is crucial for human solid tumor growth and progression.
  • Positive regulators like vascular endothelial growth factors (VEGF) drive tumor neovascularization.
  • Targeting angiogenesis offers a promising therapeutic strategy for cancer treatment.

Purpose of the Study:

  • To review the significance of VEGF as a therapeutic target in human solid tumors.
  • To discuss various therapeutic tools available for controlling VEGF function.
  • To highlight the role of VEGF in promoting tumor neovascularization.

Main Methods:

  • Literature review of recent studies on angiogenesis and VEGF.
  • Analysis of therapeutic strategies targeting VEGF.
  • Discussion of the mechanisms by which VEGF promotes tumor growth.

Main Results:

  • VEGF is a critical mediator of tumor angiogenesis.
  • Several therapeutic approaches exist to inhibit VEGF signaling pathways.
  • Controlling VEGF function is essential for effective anti-cancer therapies.

Conclusions:

  • VEGF represents a highly promising therapeutic target for human solid tumors.
  • Effective control of VEGF is vital for inhibiting tumor neovascularization and growth.
  • Further research into VEGF-targeted therapies can improve cancer treatment outcomes.

More Related Videos

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies09:03

Modified In Vivo Matrix Gel Plug Assay for Angiogenesis Studies

Published on: June 30, 2023

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis09:33

Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis

Published on: March 20, 2026

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...